Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency

Nima Parvaneh; Shohreh Shahmahmoudi; Hamideh Tabatabai; Mohsen Zahraei; Taha Mousavi; Abdol-Reza Esteghamati; Mohammad M Gooya; Setareh Mamishi; Rakhshandeh Nategh; Olen M Kew

doi:10.1016/j.jcv.2007.04.002

Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency

J Clin Virol. 2007 Jun;39(2):145-8. doi: 10.1016/j.jcv.2007.04.002. Epub 2007 May 16.

Authors

Nima Parvaneh¹, Shohreh Shahmahmoudi, Hamideh Tabatabai, Mohsen Zahraei, Taha Mousavi, Abdol-Reza Esteghamati, Mohammad M Gooya, Setareh Mamishi, Rakhshandeh Nategh, Olen M Kew

Affiliation

¹ Department of Pediatrics, Infectious Disease Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 17509935
DOI: 10.1016/j.jcv.2007.04.002

Abstract

Vaccine-associated paralytic poliomyelitis (VAPP) is a rare complication of oral polio vaccine. We describe a fatal case of VAPP in an 8-month-old boy with Major Histocompatibility Class II deficiency. The isolated poliovirus was a Sabin type 2-type 1 recombinant that showed 1.4% VP1 divergence from Sabin type 2.

Publication types

Case Reports

MeSH terms

Enzyme-Linked Immunosorbent Assay
Fatal Outcome
Histocompatibility Antigens Class II*
Humans
Immunocompromised Host*
Immunologic Deficiency Syndromes / complications*
Infant
Male
Poliomyelitis / etiology*
Poliomyelitis / prevention & control
Poliovirus Vaccine, Oral / adverse effects*
Poliovirus Vaccine, Oral / immunology
Polymerase Chain Reaction

Substances

Histocompatibility Antigens Class II
Poliovirus Vaccine, Oral